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1. Introduction
The concept of nanoparticle-based drug 
delivery dates back to the 1970s, but 
Abraxane was the first drug delivery nano-
particle to reach routine clinical use in 
2005. Over the past decade, new concepts 
for nanoparticle-based therapies have 
emerged; for example, the combination of 
both therapeutic and diagnostic capabili-
ties in a single carrier (i.e., theranostics).[1] 
Today, numerous nanoparticles are in clin-
ical development for a broad range of indi-
cations, including hypercholesterolemia, 
seasonal influenza, diabetes, smoking 
cessation, and cancer.[2] Nanoparticles 
designed for the treatment of solid tumors 
are typically in the 100 nm size range and 
exploit the leaky vasculature and reduced 
lymphatic drainage of tumors to achieve 
passive targeting,[3] a phenomenon known 
as the “enhanced permeation and reten-
tion” effect.[4] The use of active targeting 
moieties can promote further increases in 
drug concentrations within the tumor.
However, tumor-associated macro-
phages, as well as professional macro-
phages in the blood, liver (Kupfer cells), lung (alveolar mac-
rophages), and spleen, are key contributors to nanoparticle 
clearance. This clearance is a major problem for nanoparticles 
designed for intracellular targeting of tumor cells because it 
diverts them from their intended sites of action, resulting in 
increased side effects, diminished therapeutic efficacy and, 
indeed, a potentially adverse tumor response. For example, 
nanoparticle-induced C5a anaphylatoxin increases macrophage 
uptake[5] as well as stimulates tumor growth by suppressing 
CD8+ T cells.[6] Conversely, targeting tumor-associated mac-
rophages[7,8] or exploiting particulate-mediated immune modu-
lation can be used to manipulate the tumor microenvironment 
or to moderate (cancer-associated) inflammatory responses, 
respectively.[9] Thus, an appropriate design and assessment of 
the (nano)particle is necessary to achieve the intended biolog-
ical outcome; this includes the metabolic assessment of mac-
rophage responses to nanoparticles.
Recent findings have established metabolic reprogramming 
as a key element of the functional behavior of macrophages, 
so that metabolism is now viewed as more than just energy 
generation and biosynthesis.[10,11] In particular, the activa-
tion of macrophages by different environmental signals (e.g., 
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lipopolysaccharide and interleukins, resulting in M1 and M2 
macrophages, respectively) has a known association with 
marked alterations in cellular metabolism.[12,13] These altera-
tions can ideally be followed using metabolomics, as this 
approach permits the unbiased and simultaneous detection of 
a wide range of cellular metabolites in response to a stimulus, 
including nanoparticles.[14] High resolution nuclear magnetic 
resonance (NMR) is an exquisite and extremely powerful tool 
for metabolomics, despite its inherent sensitivity limitations. 
NMR shows unparalleled analytical reproducibility and imparts 
the ability to obtain unequivocal structural and quantitative 
information on metabolites involved in central metabolic path-
ways. NMR-based metabolomics is well established in disease 
profiling and drug development studies,[15] and the literature 
reporting the use of this technique for assessment of cellular 
responses to nanoparticles continues to increase (reviewed by 
Lv and co-authors).[16] However, the metabolic responses of 
macrophages to nanoparticles are poorly characterized and, to 
our knowledge, the only previous study examining macrophage 
metabolomic changes was conducted with ultrasmall iron oxide 
nanoparticles).[17]
Here, we use NMR metabolomics to assess the impact of 
different nanoparticles on macrophage metabolism, to uncover 
nanoparticle-induced metabolic activation profiles. For this 
study, we have selected three types of nanoparticles [made from 
silk, poly(lactic-co-glycolic acid) (PLGA), or silica] with diam-
eters within a 100–125 nm size range; these types of nano-
particle are presently at various stages of preclinical and clin-
ical development for biomedical applications (e.g., solid tumor 
targeting, smoking cessation[2]). While silk nanoparticles have 
been recently proposed as promising drug delivery platforms,[18] 
nanoparticles made of PLGA (a synthetic polymer approved for 
human use by Food and Drug Administration and European 
Medicines Agency) are among the most successful vectors for 
delivery of biomolecules and drugs in the clinical setting.[19] 
On the other hand, silica nanoparticles are being increasingly 
explored for both drug delivery and bioimaging applications.[20] 
We have used RAW 264.7 macrophages for this study because 
this cell line has emerged as a valuable model for assessing 
macrophage responses to various stimuli, and their use permits 
direct comparison to other studies.[21–26] The changes in the 
intracellular and extracellular metabolomes of macrophages, at 
different nanoparticle concentrations and exposure times, were 
assessed by 1H NMR analysis of cell extracts and culture media.
2. Results
2.1. Impact of Nanoparticles on Cellular Morphology  
and TNF-α Release
Qualitative scanning electron microscopy studies were per-
formed on both nanoparticle preparations (Figure 1a) and 
nanoparticle exposed cells (Figure 1b); all nanoparticles were 
spherical, uniform and of the expected size. Cells exposed to 
nanoparticle preparations at selected concentrations showed 
substantial differences. Cells were tightly “coated” by silica and 
silk nanoparticles. Furthermore, silk nanoparticles, besides 
their tight coating behavior, also showed “loose” packing 
(Figure 1b, asterisk). Cells exposed to PLGA nanoparticles 
showed no signs of cell coating, instead showing loose packing 
around the cells (Figure 1b). Loose nanoparticle packing was 
never observed for silica nanoparticles in any of the examined 
samples. However, for silk and PLGA nanoparticles, this loose 
packing was often lost during sample preparation (data not 
shown), suggesting that these structures were fragile. Higher 
resolution images showed substantial interaction of silica and 
silk nanoparticles with the plasma membrane of the RAW 264.7 
cells (Figure 2a,b). Cells exposed to silk nanoparticles showed a 
range of cell morphologies including a migratory phenotype, 
with signs of lamellipodium formation (Figure 2b closed arrow) 
and membrane ruffles (Figure 2b open arrow); these features 
were absent in the silica-treated cells. Cells exposed to nanopar-
ticles at 10 µg mL−1 showed similar morphologies for all treat-
ment groups (Figure S1, Supporting Information) and were 
indistinguishable from the control cells (Figure 1b).
The TNF-α release was measured in conditioned medium 
following exposure of RAW 264.7 cells to nanoparticles 
(Figure 2d). Treatment with any of the nanoparticles at 
10 µg mL−1 caused no significant change in TNF-α release 
when compared to control cultures. However, a silica nano-
particle concentration of 500 µg mL−1 triggered the highest 
TNF-α release. Significantly lower release was measured for 
cells treated with PLGA nanoparticles and release was even 
lower for cells treated with silk nanoparticles (P < 0.01 for 
PLGA versus silk). The response of RAW 264.7 cells to lipopoly-
saccharide was used as a positive control. Scanning electron 
microscopy imaging showed that lipopolysaccharide activation 
and subsequent TNF-α release was not coupled to changes in 
cell morphology (Figure 2c,d).
2.2. Impact of Nanoparticles on the Intracellular Metabolome
A typical 1H NMR spectrum of macrophage aqueous extract 
(Figure 3) shows contributions from several tens of metabolites, 
from which nearly 40 were unequivocally identified (Table S1, 
Supporting Information). Principal component analysis (PCA) 
was applied to the spectra to explore data and grouping trends. 
The main sources of variability accounting for sample dis-
tribution in the resulting scores scatter plot (Figure 4) were 
culture time and nanoparticle concentration. Indeed, sample 
scores along PC1, which explained 30% of the variance, were 
related to culture time, with 24 h samples clustering together 
in negative PC1 and separating from the 48 and 72 h samples 
(Figure 4a). PC2 (explaining 22% of the variance) separated 
samples exposed to the high nanoparticle concentration (posi-
tive PC2) from the controls and the samples exposed to the low 
nanoparticle concentration (negative PC2) (Figure 4b). No clus-
tering according to nanoparticle type was apparent, regardless 
of the PCs being considered.
As culture time appeared to be a key factor, multivariate 
modeling was conducted for each individual time point. The 
PCA score plots (Figure S2, Supporting Information) allowed 
two observations, namely (i) the samples exposed to low nano-
particle concentrations overlapped with controls at all times, 
while separating from high concentration samples along PC1; 
and (ii) a trend was observed for sample separation according 
Adv. Healthcare Mater. 2017, 1601240
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to nanoparticle type, especially at 72 h, where, with the excep-
tion of one PLGA sample, three distinct clusters appeared for 
silk, PLGA, and silica nanoparticle-exposed samples, separated 
along PC4.
These PCA results were used to construct partial-least 
squares discriminant analysis (PLS-DA) models for individual 
time points and each nanoparticle type, considering two 
classes—control and high nanoparticle concentration—in order 
to highlight nanoparticle-specific metabolic variations. The low 
concentration samples were not considered further, as their 
metabolic profiles were very similar to the controls. The PLS-DA 
scores and loading plots obtained for 24 h samples are shown 
in Figure 5; the results for 48 and 72 h samples are presented 
in Figures S3 and S4 (Supporting Information). In all cases, the 
controls were clearly discriminated from nanoparticle-exposed 
samples with high robustness (Q2 > 0.5). Inspection of the load-
ings explaining sample discrimination along the first latent 
variable (LV1) allowed ready identification of the main meta-
bolic differences. The 24 h exposure showed loading profiles 
(Figure 5, left) indicating that some effects, such as increases 
in creatine and phosphocreatine (red-negative loadings) and 
decreases in aspartate, betaine, and myo-inositol (red-positive 
Adv. Healthcare Mater. 2017, 1601240
Figure 1. Representative scanning electron micrographs of nanoparticles and cells. a) Nanoparticles (scale bar: 500 nm) and b) RAW 264.7 cells 
exposed to nanoparticles (500 µg mL−1) after a 24 h exposure. Asterisks denote examples of nanoparticle coatings that loosely (PLGA and silk) and 
tightly (silica) wrap the cells (scale bar: 10 µm).
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loadings), were common to the three nanoparticle types. How-
ever, some variations appeared to be nanoparticle-specific. For 
instance, an increase in glutamine was only observed for silica 
nanoparticles, whereas glycine showed opposite variations 
in silk and silica nanoparticle-exposed cells. The loading pro-
files for 48 and 72 h shared many common features with the 
24 h data sets, though a few additional material-specific varia-
tions were evident at the later time points (e.g., phosphocho-
line, glycerophosphocholine; Figures S3 and S4, Supporting 
Information).
Spectral integration results were summarized in a 
heatmap showing the percentage variation to assess the 
magnitude and significance of differences in individual 
metabolites for each exposure time and nanoparticle type 
when compared to controls (Figure 6 and Table S2, Sup-
porting Information). Only the metabolites with a represent-
ative large effect size (i.e., absolute value >0.8, justified in 
ref. [27]) were included.
All nanoparticles caused significant changes in metabolites 
involved in glycolysis and the tricarboxylic acid (TCA) cycle. In 
particular, pyruvate was decreased in cells exposed to silk nano-
particles (up to 30%), while lactate was increased in all treated 
cells (up to 284% in cells exposed to silk and up to 182% and 
131% in cells exposed to PLGA and silica nanoparticles, respec-
tively). Itaconate and succinate were also increased, particularly 
in cells exposed to PLGA nanoparticles.
The intracellular levels of several amino acids were altered 
in macrophages exposed to nanoparticles. Aspartate, glutamate, 
alanine, and threonine were consistently decreased in exposed 
samples, regardless of nanoparticle type (blue patches in the 
heatmap, Figure 6). By contrast, lysine, branched chain amino 
acids (valine, leucine, isoleucine) and aromatic amino acids 
(tyrosine, phenylalanine) showed time-dependent increases, 
which were generally of higher magnitude in cells incubated 
with silk nanoparticles than with other nanoparticles (orange/
red patches in the heatmap, Figure 6). The variations in glu-
tamine and glycine were clearly dependent on nanoparticle 
type. Glutamine increased significantly in cells exposed to 
silica nanoparticles for 24 h, followed by normalized levels at 
longer exposure periods. Silk nanoparticle exposure caused a 
transient glutamine decrease at 48 h, while PLGA nanoparticle 
exposure had no effect on glutamine levels. Alterations in gly-
cine included a decrease at 24 h in response to silica nano-
particles and substantial increases at 48 h with silk and PLGA 
nanoparticles.
The levels of energy-related metabolites were greatly affected 
in nanoparticle exposed cells. Cellular ATP decreased fol-
lowing exposure to all nanoparticle types for 48 h or longer, 
while significant increases in creatine (69% to 541%) and phos-
phocreatine (36% to 482%) were evident, especially for the 
shorter exposure times. Comparison of the three nanoparticle 
types revealed that silk and silica nanoparticles produced the 
greatest change in creatine and phosphocreatine levels, with 
lesser changes occurring in the cells treated with PLGA nano-
particles. Indeed, after a 72 h exposure to PLGA nanoparticles, 
the intracellular levels of creatine and phosphocreatine were, 
respectively, similar or lower relative to controls, highlighting 
the time-dependent and dynamic nature of the metabolome 
changes.
Other prominent variations included a consistent decrease 
in myo-inositol, together with time- and material-dependent 
variations in choline compounds, taurine and betaine. Phos-
phocholine and glycerophosphocholine decreased in mac-
rophages exposed to silk or silica nanoparticles, while PLGA 
nanoparticles promoted an increase in glycerophosphocho-
line and no change in phosphocholine. Taurine and betaine 
showed reduced levels in cells exposed to PLGA or silica nan-
oparticles for 24 h, but increased if exposure was increased 
to 72 h.
Adv. Healthcare Mater. 2017, 1601240
Figure 2. Macrophage response to nanoparticles. Representative scan-
ning electron micrographs of RAW 264.7 cells exposed to a) silica and b) 
silk nanoparticles for 24 h (scale bar: 10 µm). Closed arrows denote the 
exposed cell plasma membrane. Silica and silk nanoparticles extensively 
covered the cells with some visible membrane ruffles (silk, open arrow). 
c) Examples of control cells (left panel) and cells exposed to lipopolysac-
charide (LPS) (arrows) (right panel) (scale bar: 5 µm). d) Tumor necrosis 
factor alpha (TNF-α) release into the cell culture medium following a 
24 h exposure to nanoparticles. Statistical analysis included an ANOVA 
followed by Bonferroni’s multiple comparison post hoc test (bars above 
samples) and Dunnett’s post hoc test using the control sample as a refer-
ence point (n = 3, ± SD).
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2.3. Impact of Nanoparticles on the Extracellular Metabolome
The cellular metabolism of macrophages exposed to nano-
particles was further analyzed by measuring cell-mediated 
variations in the culture medium composition (Figure 7; 
Table S3, Supporting Information). Compared to control cells, 
macrophages exposed to nanoparticles for 48 h or longer con-
sumed more glucose, thereby decreasing the glucose levels in 
their respective media. Lactate and itaconate excretion was also 
higher from exposed cells than from control cells, whereas the 
release of pyruvate was significantly reduced in cells exposed 
for 72 h. Citrate excretion was also lower at the same exposure 
duration, except for macrophages exposed to silica nanoparti-
cles, where citrate levels remained comparable to those of the 
control cells.
The conditioning medium surrounding exposed cells dif-
fered from the control medium with respect to the levels of 
several amino acids. The control cells consumed glutamine, 
valine, leucine, isoleucine, and methionine, unlike nanoparticle 
exposed cells; especially at the 24 h time point, silica nano-
particles induced hydrolysis/consumption of alanyl-glutamine 
coupled with the corresponding large increases in free extracel-
lular alanine and glutamine (which also increased inside the 
cells). Extracellular alanine further increased at 48/72 h, indi-
cating its increased excretion by exposed cells. Glycine excre-
tion, on the other hand, only increased in the medium of cells 
exposed to silk nanoparticles. Note, however, that incubation 
of medium alone with silk nanoparticles (without cells) did 
not result in any change in glycine levels. A few amino acids 
showed invariant levels in control cells (neither consumed nor 
excreted) but increased their levels in the conditioning medium 
when the cells were exposed to nanoparticles; these were threo-
nine, lysine, tyrosine, and phenylalanine.
Overall, the nanoparticles-modulated macrophage metabo-
lism that was indicative of the M1-like phenotype.[13,28] There-
fore surface expression of CD80 and cytokine production in 
response nanoparticles was assessed (Figure 8a,b).[29] All nano-
particles induced the plasma membrane expression of CD80, 
with similar levels observed for silica and silk (25% of CD80 
positive cells) and significantly higher levels for PLGA (39% 
of CD80 positive cells); lipopolysaccharide (LPS) served as the 
positive control (>90% CD80 positive cells). Conditioned cell 
culture medium from nanoparticle-treated and LPS-treated 
cells showed upregulation of (proinflammatory) cytokines 
(Figure 8c). For example, all nanoparticles and LPS induced 
substantial increases in IL-1ra, CCL3, and CCL4, but the nano-
particles failed to increase GM-CSF, IL10, and IL6 above the 
detection limit of this assay.
3. Discussion
Nanoparticles can be delivered into the body using a range of 
administration routes (e.g., intravenous, inhaled, subcutaneous, 
etc.), with the view of evoking the desired therapeutic response. 
Targeting specific macrophage populations could be part of a 
therapeutic strategy, or it could simply be an inadvertent con-
sequence of a serendipitous nanoparticle design. Macrophage 
Adv. Healthcare Mater. 2017, 1601240
Figure 3. 500 MHz 1H NMR spectrum of an aqueous extract from RAW 264.7 control cells. Some assignments are indicated: three-letter code used 
for amino acids, ADP adenosine diphosphate, ATP adenosine triphosphate, AXP (ADP/ATP), Bet betaine, Cr creatine, GPC glycerophosphocholine, 
GSH reduced glutathione, m-Ino myo-inositol, NAD+ oxidized nicotinamide adenine dinucleotide, PC phosphocholine, PCr phosphocreatine, UXP 
(UDP/UTP uridine diphosphate/ uridine triphosphate).
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responses toward nanoparticles depend on multiple factors; 
these include, but are not limited to, the bulk material and sur-
face modification (chemical and/or physical), as well as particle 
size, geometry, exposure time, and dose (reviewed in ref. [30]). 
Thus, selecting synthetic, inorganic, and biopolymer based 
nanoparticles for comparative metabolomic assessment can 
be challenging and, to the best of our knowledge, has not been 
attempted before.
In this study, we assessed nanoparticles that were in the 
100 nm size range because clinically approved (e.g., Abraxane, 
130 nm) and emerging (e.g., Bind-014, 100 nm, developed by 
BIND Therapeutics) nanoparticles for anticancer drug delivery 
are all within this size range.[1,31] Furthermore, particles in the 
100 nm size range are also capable of efficiently exploiting the 
enhanced permeation and retention effect for passive tumor 
targeting.[3] The maximum dose (500 µg mL−1) and 72 h 
exposure time were selected to emulate the clinical pharma-
cokinetics observed with synthetic nanoparticles in man.[31] In 
the current study, we worked with nanoparticles made from 
PLGA, silica, and silk. We selected PLGA because many nan-
oparticles currently in clinical development use this synthetic 
polymer;[2,19] furthermore, PLGA has a track record for use in 
humans. Silica was selected as an inorganic material. Although 
there is much excitement about the perceived benefit(s) of silica 
for nanomedicine applications,[20,32] its track record is contro-
versial. Previous in vitro and in vivo studies have indicated that 
silica nanoparticles can readily induce toxicity and alter cellular 
metabolism.[33–36] In addition to the synthetic polymer and the 
inorganic material, we included the biopolymer silk.[37] Over 
the past decade, silk has emerged as a promising contender for 
drug delivery applications.[18,38,39] First, silk has a track record 
for use in humans; it is biocompatible and biodegradable.[38,40] 
Second, silk can be readily processed into many different for-
mats, including nanoparticles that can be used for lysosomo-
tropic drug delivery.[41] Third, it is possible to fine tune drug 
release from silk.[41,42] Furthermore, silk has remarkable prop-
erties that stabilize therapeutic proteins, as the nanocrystal-
line regions in the silk structure perform several functions, 
including providing a buffering capacity, tailoring water content 
at the nanoscale and providing physical protection (reviewed in 
ref. [43]).
Macrophages exposed to silk, PLGA, and silica nanoparti-
cles showed marked deviations from the basal macrophage 
metabolic profile. These changes included higher glucose 
consumption and lactate production, suggesting increased 
glycolytic activity, as previously reported for macrophages 
exposed to ultrasmall superparamagnetic particles of iron 
oxide (USPIOs),[17] airborne particulate matter,[44] or bacte-
rial lipopolysaccharide.[13,45] The TCA cycle was also clearly 
affected, especially upon exposure to PLGA nanoparticles, as 
indicated by significant increases in itaconate and succinate 
(Figure 9). Itaconate has been identified in lipopolysaccha-
ride-activated (M1) macrophages[13,28] and is generated by the 
decarboxylation of the citrate-derived metabolite cis-aconi-
tate,[46] following a TCA cycle breakpoint at isocitrate dehydro-
genase.[47] The functional role of this metabolite has not been 
fully elucidated, but it is thought to be an important mediator 
of the immune defense mounted by macrophages.[48] Suc-
cinate, which is known to have a proinflammatory role,[49] 
is also elevated in M1 macrophages,[13] likely in relation to a 
second TCA cycle breakpoint at succinate dehydrogenase.[47] 
The observed changes in metabolism suggest a M1-like mac-
rophage phenotype. Upregulation of CD80 expression and 
cytokine levels (Figures 2 and 8) strongly supported the notion 
that these nanoparticles induced metabolic reprogramming 
through M1-like macrophage activation. Conceivably, the sig-
nificant differences in CD80 upregulation and TNF-α secre-
tion seen in response to nanoparticle treatment could have 
arisen in part due to macrophage heterogeneity, and the extent 
of activation (i.e., the signaling threshold) quite likely deter-
mined the overall biological performance.[50] For example, 
TNF-α release is influenced by many factors (e.g., material, 
dose, particle size, etc.); thus, the differences observed here 
simply serve as an overall performance indicator.[21,25] We 
Adv. Healthcare Mater. 2017, 1601240
Figure 4. Scores scatter plots resulting from applying PCA to the 1H NMR 
spectra from cell aqueous extracts: a) scores colored by culture time and 
b) scores colored by nanoparticle concentration.
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speculate that the differences in TNF-α are due to the mate-
rial per se, because we controlled the nanoparticle size, shape, 
and concentration.
The nanoparticles tested caused profound changes in the 
levels of several amino acids. Aspartate and glutamate, and 
to a lesser extent alanine and threonine, were consistently 
Adv. Healthcare Mater. 2017, 1601240
Figure 5. Multivariate analysis of 1H NMR spectra from aqueous extracts of control cells and cells exposed for 24 h to a) silk nanoparticles, b) PLGA 
nanoparticles, or c) silica nanoparticles: partial-least squares discriminant analysis (PLS-DA) scores scatter plots (left) and LV1 loadings w colored as 
a function of variable importance in the projection (right).
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decreased in exposed macrophages, regardless of the nano-
particle type. This could reflect their use in replenishing the 
TCA cycle, namely through the aspartate arginosuccinate 
shunt (Figure 9). Indeed, this pathway has been shown to fuel 
the reprogrammed TCA cycle of inflammatory macrophages, 
playing an important role in their effector functions.[47] Our 
results also showed that exposed macrophages consumed less 
glutamine from the medium when compared to control cells. 
This contrasts with the results reported for lipopolysaccharide-
stimulated macrophages, where glutamine influx and oxida-
tion were increased,[13] but agrees with a recent study where 
M1 macrophages showed reduced glutaminolysis.[45] Interest-
ingly, our data further suggested that the effect of nanoparticle 
exposure on intracellular glutamine metabolism depended on 
the nanoparticle type: macrophages exposed to silk for 48 h 
showed decreased glutamine levels, whereas those exposed to 
silica for 24 h presented higher levels of this amino acid; PLGA 
nanoparticles had no effect on glutamine levels. The variations 
in glycine levels were also suggestive of nanoparticle-specific 
effects. We speculate that intracellular proteolytic degradation 
of silk nanoparticles is responsible for the increase in glycine 
because glycine makes up nearly 50% of silk fibroin.[51] How-
ever, we currently have no experimental proof for this expla-
nation. All tested nanoparticles induced increases in lysine, 
branched chain, and aromatic amino acids, which could pos-
sibly reflect autophagic protein degradation. Indeed, a variety 
of nanoparticles have been shown to induce autophagy, leading 
either to increased cell death or, paradoxically, to promotion of 
cell survival.[52]
In the current study, cellular ATP levels were maintained in 
the first 24 h of exposure but these levels decreased with longer 
incubations and with all nanoparticle types. This is consistent 
Adv. Healthcare Mater. 2017, 1601240
Figure 6. Heatmap of main metabolite variations in aqueous extracts of cells exposed to silk, PLGA or silica nanoparticles (500 µg mL−1) for different 
time periods (24, 48, and 72 h), in relation to controls (color scale reflecting % variation). The criterion for including a metabolite in the heatmap was 
absolute effect size >0.8 (and standard error < effect size). Statistically significant differences are indicated (*p < 0.05, **p < 0.01).
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with the TCA cycle reprogramming described above: first, the 
inhibition of succinate dehydrogenase (complex II of the res-
piratory chain) is expected to decrease ATP generation through 
oxidative phosphorylation;[10] second, as recently shown for 
lipopolysaccharide-activated macrophages, the itaconate 
produced by exposed macrophages could abolish mitochondrial 
substrate-level phosphorylation.[48] Our results further showed 
huge (up to sixfold) increases in creatine and phosphocreatine 
in cells exposed for 24 or 48 h, followed by a lower increase or 
even a decrease at 72 h (depending on the nanoparticle type). 
Increases in these metabolites were also reported in mac-
rophages activated with lipopolysaccharide[53] or exposed to 
ultrasmall superparamagnetic particles of iron oxide.[17] Phos-
phocreatine is a reusable high energy phosphate reservoir and 
becomes particularly important in situations of high metabolic 
demand, when the rate of ATP use exceeds its generation by 
other metabolic pathways.[54] Early work has shown that the dif-
ferentiation of monocytes into macrophages is accompanied 
by the expression of creatine kinase and the development of a 
large phosphocreatine pool,[55] which is rapidly used up during 
phagocytosis.[56] Hence, our results suggest that macrophages 
stimulated by nanoparticles rely on the creatine kinase/phos-
phocreatine system for energy buffering, maintenance of cel-
lular homeostasis and phagocytic function.
Noticeable changes occurred in common osmolytes and/or 
membrane-related compounds. The decrease in myo-inositol—
observed for all nanoparticles and time points and previously 
reported in macrophages exposed to particulate matter[44]—may 
reflect the role of this metabolite is osmoregulation and/or in 
phosphoinositide turnover and cell signaling. Membrane modi-
fication was further supported by decreases in phosphocholine 
and glycerophosphocholine levels in cells exposed to silk or 
silica nanoparticles, in accordance with observations made for 
USPIO-exposed macrophages.[17] PLGA nanoparticles did not 
affect phosphocholine levels and caused an increase in glyc-
erophosphocholine, which may also act as osmoprotectant, in 
agreement with the less substantial interaction of these par-
ticles with the plasma membrane observed by scanning elec-
tron microscopy. The initial decrease in taurine and betaine, 
followed by an increase at 72 h, could reflect the role of these 
metabolites in maintaining the osmotic balance, as well as their 
antioxidant activity. Indeed, taurine is especially abundant in 
inflammatory cells, such as activated macrophages, where it 
provides protection during processes that generate oxidants.[57] 
This is plausible because a nanoparticle-mediated M1-like phe-
notype was observed here.
4. Conclusion
We assessed the metabolomic response of macrophages toward 
silk, PLGA, and silica nanoparticles that are in preclinical 
Adv. Healthcare Mater. 2017, 1601240
Figure 7. Heatmap of main metabolite variations in the culture medium of cells exposed to silk, PLGA or silica nanoparticles (500 µg mL−1) for different 
time periods (24, 48, and 72 h), in relation to controls (color scale reflecting % variation). The criterion for including a metabolite in the heatmap was 
absolute effect size >0.8 (and standard error < effect size). Statistically significant differences are indicated (*p < 0.05, **p < 0.01).
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and clinical development for drug delivery applications. The 
observed upregulation of glycolysis, altered TCA cycle activity 
(with increased production of itaconate and succinate, and acti-
vation of amino acid catabolic routes) together with reduced 
ATP generation were consistent with a proinflammatory 
M1-like phenotype. Furthermore, aminoacids possibly derived 
from autophagy, the creatine kinase/phosphocreatine system 
and a few metabolites acting as osmolytes and/or antioxidants 
emerged as important players in the metabolic reprogram-
ming of macrophages exposed to nanoparticles. This metabolic 
signature was a common response to all nanoparticles tested; 
however, the direction and magnitude of some variations 
were clearly nanoparticle specific, indicating material-induced 
biological specificity. Further metabolomic changes are also 
expected once a payload is added to the carrier.[58] Overall, this 
study provides a benchmark for metabolic changes induced by 
unmodified silk, PLGA, and silica nanoparticles, and demon-
strates the value of NMR metabolomics to assess nanoparticle-
induced metabolic reprogramming of macrophages.
5. Experimental Section
Preparation and Characterization of Nanoparticles: Bombyx mori silk was 
extracted from cocoons and used to manufacture silk nanoparticles, as 
described previously;[41,59] silk nanoparticle manufacture is presented in 
video format in ref. [60]. Briefly, cocoons were cut into 5 × 5 mm pieces, 
degummed for 60 min and the resulting silk fibres were rinsed in ddH2O 
and air dried. The fibres were then dissolved in 9.3 M LiBr solution at 
60 °C for 4 h. This solution was dialyzed (molecular weight cut off 3500) 
against ddH2O to remove the LiBr salt. The resulting aqueous silk 
solution was cleared by centrifugation and the aqueous silk (5 wt%) 
solution was added dropwise (20 µL per drop) to acetone, maintaining a 
>75% v/v acetone volume. The precipitated silk was then centrifuged, the 
supernatant was aspirated, and the pellet was resuspended in ddH2O. 
After vortexing, the suspension was sonicated twice for 30 s at 30% 
amplitude with a Sonoplus HD 2070 sonicator (ultrasonic homogenizer, 
Bandelin, Berlin, Germany). The centrifugation, washing, and 
resuspension steps for the silk nanoparticle preparation were repeated 
at least twice more. The final silk nanoparticles were 104 ± 1.7 nm in 
size and had a zeta potential of −56 mV, determined by dynamic light 
scattering (Zetasizer Nano-ZS Malvern Instrument, Worcestershire, 
U.K.) in ddH2O, as detailed previously.
[59] The silk nanoparticles were 
stored at 4 °C until use. PLGA (124 ± 0.05 nm, Phosphorex, Hopkinton, 
MA, USA) and amine-surface modified silica particles (101 ± 7.4 nm, 
NanoComposix San Diego, CA, USA) were purchased and used as 
supplied. All cell culture studies used 10 mg mL−1 nanoparticle stocks 
prepared in ddH2O and then diluted in cell culture medium as indicated.
Scanning Electron Microscopy: The nanoparticles were visualized by 
scanning electron microscopy, as detailed previously.[59] Nanoparticles 
were diluted with distilled water to a concentration of 1 mg mL−1. 
The samples were then pipetted onto a silicon wafer and lyophilized 
overnight. The specimens were sputter coated with a 20 nm layer of 
gold using an ACE200 low vacuum sputter coater (Leica Microsystems, 
Wetzlar, Germany) and analyzed with an FE-SEM SU6600 (Hitachi High 
Technologies, Krefeld, Germany) at 5 kV and a 40 000-fold magnification. 
Cell imaging studies were conducted on RAW 264.7 cells seeded onto 
Figure 8. Nanoparticle induced M1-like macrophage phenotype. a) Plasma membrane expression of CD80, b) percentage CD80 positive macrophages, 
and c) expression of cytokines in response to stimuli. All data for 24 h exposure to 500 µg mL−1 nanoparticles and 100 ng mL−1 LPS, respectively. 
Statistically significant differences are indicated (n = 3, ± SD) (***p < 0.001).
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glass coverslips and incubated overnight as detailed below. Cells were 
then exposed to the desired treatments for 24 h, followed by fixation with 
2% v/v glutaraldehyde in phosphate buffer saline (PBS), washing with 
ddH2O twice, dehydration with an increasing ethanol series, and critical 
point drying (EM CPD300, Leica Microsystems, Wetzlar, Germany), as 
detailed elsewhere.[61] Samples were then sputter-coated with gold and 
analyzed by scanning electron microscopy at 5 kV at 2500, 3500, and 
4500-fold magnification.
Routine Cell Culture Maintenance: The murine macrophage RAW 
264.7 cell line was purchased from ATCC (Manassas, VA, USA). Cells 
were cultured in Dulbecco’s Modified Eagle Medium (containing 
4.5 g glucose, 110 mg sodium pyruvate, 10% v/v fetal bovine serum) 
in a humidified 5% CO2 atmosphere at 37 °C. The cultures were 
routinely subcultured every 2–3 d (when they reached 80% confluency) 
by scraping the cells off the flask and replating them at a split ratio of 
2:10 on tissue culture-treated polystyrene (Corning, New York, NY, 
USA), unless otherwise stated. For nanoparticle macrophage studies 
cells were routinely seeded at a density of 1.5 × 104 cells cm−2. All cell 
culture studies were performed in accordance with the best practice 
guidelines;[62] here, the cells were cultured for up to ten passages and 
then replaced with a new validated cryostock.
Tumor Necrosis Factor Alpha (TNF-α) Assay: Macrophage TNF-α 
release was assessed as detailed previously.[59] Briefly, RAW 264.7 cells 
were seeded and allowed to recover overnight, as described above. The 
culture medium was then aspirated and replaced with fresh medium 
containing either (i) 15 ng of lipopolysaccharide (Sigma-Aldrich, St. 
Louis, MO, USA), (ii) control medium, or (iii) nanoparticles made of 
silk, PLGA or silica at concentrations of 10 µg mL−1, and 500 µg mL−1. 
Cultures were incubated for 24 h and then the medium was collected 
and centrifuged at 6000 × g for 5 min. Assay samples were stored at 
−80 °C and analyzed using a mouse TNF-α DuoSet ELISA (R&D 
Systems, Minneapolis, MN, USA), according to the manufacturer’s 
instructions. Data were analyzed using GraphPad Prism 5.0b (GraphPad 
Software, La Jolla, CA, USA). Sample pairs were analyzed with the 
Student’s t test. Multiple samples were evaluated by one-way analysis 
of variance (ANOVA) followed by Bonferroni’s multiple comparison 
post hoc test or the Dunnett’s post hoc tests to evaluate the statistical 
differences between the samples and controls.
Assessment of Macrophage Activation: Cells were seeded and allowed 
to recover over night as detailed above. Next, cultures were incubated 
with nanoparticles (500 µg mL−1) for 24 h and then the cells were 
placed on ice, detached by scraping, harvested into 5 mL falcon tubes 
and centrifuged at 350 × g at 4 °C for 5 min. Tubes were placed on ice, 
the supernatant was discarded and cells were resuspended in either 
(i) control cell staining buffer (1 × PBS, 1% BSA), or (ii) cell staining 
buffer containing Alexa Fluor 488 (AF488) antimouse CD80 (Biolegend, 
San Diego, CA, USA, Clone 16-10A1) or AF488 Armenian Hamster IgG 
Isotype Control (Biolegend, Clone HTK888) for 20 min in the dark. 
Cells were then washed 3× in cell staining buffer by centrifugation and 
resuspended in cell staining buffer prior to data acquisition on a BD 
FACSCanto (Becton Dickinson, San Jose, CA, USA). Flow cytometry data 
were acquired using BD FACSDiva software (Becton Dickinson, San 
Jose, CA, USA) and analyzed using FlowJo v10.1 (TreeStar, San Carlos, 
CA, USA). All flow cytometry histograms and CD80 population values 
were obtained using FlowJo. Porteome profilers (mouse cytokine array 
Panel A, R&D Systems, Minneapolis, MN, USA) were used according 
to the manufacturer’s instructions using 24 h conditioned medium 
(nanoparticles 500 µg mL−1 and 100 ng mL−1 LPS). For the analysis of 
arrays, blots were threshold adjusted and analyzed using ImageJ 1.38 
(National Institutes of Health, Bethesda, USA).
Sample Collection for Metabolomics: For metabolomics studies RAW 
264.7 cells were seeded as detailed above and allowed to recover overnight. 
The cells were then exposed to low (10 µg mL−1) and high (500 µg mL−1) 
nanoparticle concentrations for up to 72 h. Cell extracts were prepared as 
detailed elsewhere.[63] Briefly, at the desired time points, cells were placed 
on ice and kept at 4 °C throughout. The culture medium was collected, 
Figure 9. Diagram of main metabolic changes reflecting reprogramming of glycolysis and the TCA cycle in macrophages exposed to nanoparticles. 
The arrows indicate increases/decreases in relation to control cells. Metabolites in italic showed nanoparticle-dependent variations. IDH, isocitrate 
dehydrogenase; SDH, succinate dehydrogenase.
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clarified by centrifugation, lyophilized and stored at −80 °C until further use. 
The cells were washed with ice-cold PBS, quenched by addition of 650 µL 
methanol 80% v/v cooled to −20 °C, scraped off the dish and collected in 
an Eppendorf tube. Next, 260 µL of CHCl3 at −20 °C was added to the tube 
and vortexed, followed by addition of 260 µL of −20 °C cooled CHCl3 and 
220 µL of ddH20 to each sample. The samples were vortexed, allowed to 
rest on ice for 10 min, and then centrifuged at 2000 × g for 15 min. The 
aqueous and lipid phases were collected; the aqueous sample was dried 
under a stream of N2 and the organic phase was allowed to evaporate in a 
fume hood. All samples were stored at −80 °C until analysis.
NMR Spectroscopy: NMR analyses were conducted on dried 
medium samples and aqueous extracts after reconstitution in 
600 µL of deuterated phosphate buffer (100 × 10−3 M, pH 7.4) 
containing 0.1 × 10−3 M 3-(trimethylsilyl)propionate sodium salt, 
(TSP)-d4. A 550 µL volume of each sample was transferred into 5 mm 
NMR tubes. NMR spectra were acquired on a Bruker Avance DRX-500 
spectrometer operating at 500.13 MHz for 1H observation, at 298 K, 
using a 5 mm probe. Standard 1D 1H spectra with water presaturation 
(pulse program “noesypr1d” in the Bruker library) were recorded with 
a 7002.8 Hz spectral width, 32 k data points, a 4 s relaxation delay and 
256 scans. Spectral processing comprised exponential multiplication 
with 0.3 Hz line broadening, zero filling to 64 k data points, manual 
phasing, baseline correction, and chemical shift calibration to the TSP 
signal at 0 ppm. 2D 1H-1H total correlation (TOCSY) spectra, 1H-13C 
heteronuclear single quantum correlation spectra, and J-resolved spectra 
were also registered for selected samples to assist spectral assignment. 
The main acquisition and processing parameters for these experiments 
are provided in Table S4 (Supporting Information).
Spectral Assignment: Metabolites were identified with the aid of 2D 
spectra (Figure S5, Supporting Information) and the spectral reference 
databases BBIOREFCODE-2–0–0 (Bruker Biospin, Rheinstetten, 
Germany) and HMDB.[64] The changes in RAW 264.7 conditioned 
medium in response to nanoparticles were assessed by establishing 
baseline values for tissue culture substrate conditioned medium and for 
RAW 264.7 conditioned medium (i.e., in the absence of nanoparticles). 
These control baseline data sets were then used to identify nanoparticle-
specific changes in the conditioned culture medium. Also, medium 
samples incubated with nanoparticles (without cells) were analyzed 
to discard changes caused by direct interaction of nanoparticles with 
medium components.
Multivariate Analysis and Spectral Integration of NMR Spectra: Spectra 
were exported from Amix-Viewer (version 3.9.14, BrukerBiospin, 
Rheinstetten) and normalized by total spectral area. Using SIMCA-P 
11.5 software (Umetrics, Umeå, Sweden), the resulting data were scaled 
to Unit Variance (UV), giving equal variance to all variables. PCA and 
PLS-DA were then applied after exclusion of suppressed water and 
contaminant signals (e.g., methanol, chloroform), with a sevenfold 
internal cross validation, from which Q2 and R2 values, reflecting 
predictive capability and explained variance, respectively, were extracted 
(SIMCA-P 11.5, Umetrics, Sweden). Selected signals in the 1D spectrum 
were integrated using Amix-Viewer (version 3.9.14, BrukerBiospin, 
Rheinstetten) and normalized by the total spectral area.
For each metabolite, the percentage variation in nanoparticle-exposed 
samples was calculated relative to controls, together with the effect 
size adjusted for small sample numbers, and the respective standard 
errors.[27] The metabolite variations of large magnitude, i.e., with an 
absolute effect size greater than 0.8,[27] were expressed in a heatmap 
colored as a function of % variation using the R-statistical software. 
The difference between the means of two groups (control and exposed) 
was assessed using the nonparametric Wilcoxon rank sum test with 
continuity correction (confidence level 95%).
Supporting Information
Supporting Information is available from the Wiley Online Library or from 
the author. All data supporting this research are openly available from 
http://dx.doi.org/10.15129/39e5d0a1-65e7-4148-9990-32cb0f40d586.
Acknowledgements
This research was supported by a Research and Development Grant 
(No. 1715) from the University of Strathclyde (F.P.S. and I.F.D.) and 
by Marie Curie FP7 Career Integration Grant (No. 334134) (NanoTrac) 
within the seventh European funding programme (F.P.S.). J.D.T.’s 
Ph.D. studentship was supported through the EPSRC Doctoral 
Training Partnership (EP/M508159/1), University of Strathclyde. 
T.W.’s Ph.D. studentship was supported through a Collaborative 
International Research Programme: University of Strathclyde and 
Nanyang Technological University, Singapore. The authors would like 
to acknowledge that this work was carriered out in part at the CMAC 
National Facility, supported by a UK Research  Partnership Fund 
award from the Higher Education Funding Council for England (Grant 
HH13054). The work was also developed in the scope of the project 
CICECO-Aveiro Institute of Materials, POCI-01-0145-FEDER-007679 
(FCT Ref. UID/CTM/50011/2013), financed by national funds through 
the FCT/MEC and when appropriate cofinanced by FEDER under the 
PT2020 Partnership Agreement. The authors also acknowledge the 
Portuguese National NMR (PTNMR) Network, supported with FCT 
funds, Dr. Manfred Spraul, Bruker BioSpin (Germany), for providing 
access to NMR software and database, and Dr. Joana Carrola for 
technical support. I.F.D further acknowledges FCT/MCTES for a research 
contract under the Program “Investigador FCT” 2014.
F.P.S. and I.F.D. conceived the study. R.S. acquired, analyzed, 
and interpreted NMR data, T.W. manufactured and characterized silk 
nanoparticle as well as performed electron microscopy studies, F.P.S. 
performed cell culture studies and J.D.T. performed flow cytometry 
studies. All authors (R.S., T.W., J.D.T., B.F.J., F.P.S., and I.F.D.) designed 
research, discussed the results, and/or advised on the analysis. F.P.S. 
and I.F.D. wrote the manuscript with support from the other authors.
Keywords
macrophages, NMR metabolomics, PLGA nanoparticles, silica 
nanoparticles, silk nanoparticles
Received: November 4, 2016
Revised: February 28, 2017
Published online: 
[1] R. Duncan, R. Gaspar, Mol. Pharm. 2011, 8, 2101.
[2] C. Sheridan, Nat. Biotechnol. 2012, 30, 471.
[3] H. Maeda, H. Nakamura, J. Fang, Adv. Drug Delivery Rev. 2013, 65, 71.
[4] Y. Matsumura, H. Maeda, Cancer Res. 1986, 46, 6387.
[5] K. M. Pondman, M. Sobik, A. Nayak, A. G. Tsolaki, A. Jäkel, 
E. Flahaut, S. Hampel, B. Haken, R. B. Sim, U. Kishore, Nanomedi-
cine 2014, 10, 1287.
[6] M. M. Markiewski, R. A. DeAngelis, F. Benencia, 
S. K. Ricklin-Lichtsteiner, A. Koutoulaki, C. Gerard, G. Coukos, 
J. D. Lambris, Nat. Immunol. 2008, 9, 1225.
[7] M. A. Miller, Y.-R. Zheng, S. Gadde, C. Pfirschke, H. Zope, 
C. Engblom, R. H. Kohler, Y. Iwamoto, K. S. Yang, B. Askevold, 
N. Kolishetti, M. Pittet, S. J. Lippard, O. C. Farokhzad, R. Weissleder, 
Nat. Commun. 2015, 6, 8692.
[8] M. Niu, S. Valdes, Y. W. Naguib, S. D. Hursting, Z. Cui, Mol. Pharm. 
2016, 13, 1833.
[9] D. R. Getts, R. L. Terry, M. T. Getts, C. Deffrasnes, M. Müller, 
C. van Vreden, T. M. Ashhurst, B. Chami, D. McCarthy, H. Wu, 
J. Ma, A. Martin, L. D. Shae, P. Witting, G. S. Kansas, J. Kühn, 
W. Hafezi, I. L. Campbell, D. Reilly, J. Say, L. Brown, M. Y. White, 
S. J. Cordwell, S. J. Chadban, E. B. Thorp, S. Bao, S. D. Miller, 
N. J. C. King, Sci. Transl. Med. 2014, 6, 219ra7.
www.advancedsciencenews.com www.advhealthmat.de
1601240 (13 of 13) © 2017  The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, WeinheimAdv. Healthcare Mater. 2017, 1601240
[10] K. C. El Kasmi, K. R. Stenmark, Semin. Immunol. 2015, 27, 267.
[11] E. L. Mills, L. A. O’Neill, Eur. J. Immunol. 2016, 46, 13.
[12] J. C. Rodríguez-Prados, P. G. Través, J. Cuenca, D. Rico, J. Aragonés, 
P. Martín-Sanz, M. Cascante, L. Boscá, J. Immunol. 2010, 185, 605.
[13] J. Meiser, L. Krämer, S. C. Sapcariu, N. Battello, J. Ghelfi, 
A. F. D’Herouel, A. Skupin, K. Hiller, J. Biol. Chem. 2016, 291, 
3932.
[14] I. F. Duarte, J. Controlled Release 2011, 153, 34.
[15] D. S. Wishart, Nat. Rev. Drug Discovery 2016, 15, 473.
[16] M. Lv, W. Huang, Z. Chen, H. Jiang, J. Chen, Y. Tian, Z. Zhang, 
F. Xu, Bioanalysis 2015, 7, 1527.
[17] J. Feng, J. Zhao, F. Hao, C. Chen, K. Bhakoo, H. Tang, J. Nanopart. 
Res. 2011, 13, 2049.
[18] L. Xiao, G. Lu, Q. Lu, D. L. Kaplan, ACS Biomater. Sci. Eng. 2016, 
2, 2050.
[19] S. Sharma, A. Parmar, S. Kori, R. Sandhir, Trends Anal. Chem. 2016, 
80, 30.
[20] A. Bitar, N. M. Ahmad, H. Fessi, A. Elaissari, Drug Discovery Today 
2012, 17, 1147.
[21] S. Bancos, D. L. Stevens, K. M. Tyner, Int. J. Nanomedicine 2015, 10, 
183.
[22] J. Meng, X. Li, C. Wang, H. Guo, J. Liu, H. Xu, ACS Appl. Mater. 
Interfaces 2015, 7, 3180.
[23] T. Kusaka, M. Nakayama, K. Nakamura, M. Ishimiya, E. Furusawa, 
K. Ogasawara, PLoS One 2014, 9, e92634.
[24] R. Kalluru, F. Fenaroli, D. Westmoreland, L. Ulanova, A. Maleki, 
N. Roos, M. Paulsen Madsen, G. Koster, W. Egge-Jacobsen, 
S. Wilson, H. Roberg-Larsen, G. K. Khuller, A. Singh, B. Nyström, 
G. Griffiths, J. Cell Sci. 2013, 126, 3043.
[25] V. Thomas, B. A. Halloran, N. Ambalavanan, S. A. Catledge, 
Y. K. Vohra, Acta Biomater. 2012, 8, 1939.
[26] K. M. Waters, L. M. Masiello, R. C. Zangar, B. J. Tarasevich, 
N. J. Karin, R. D. Quesenberry, S. Bandyopadhyay, J. G. Teeguarden, 
J. G. Pounds, B. D. Thrall, Toxicol. Sci. 2009, 107, 553.
[27] L. Berben, S. M. Sereika, S. Engberg, Int. J. Nurs. Stud. 2012, 49, 
1039.
[28] C. L. Strelko, W. Lu, F. J. Dufort, T. N. Seyfried, T. C. Chiles, 
J. D. Rabinowitz, M. F. Roberts, J. Am. Chem. Soc. 2011, 133, 
16386.
[29] D. M. Mosser, X. Zhang, Curr. Protoc. Immunol. 2008, Chapter 14, 
Unit 14.2.
[30] R. Weissleder, M. Nahrendorf, M. J. Pittet, Nat. Mater. 2014, 13, 
125.
[31] J. Hrkach, D. Von Hoff, A. M. Mukkaram, E. Andrianova, J. Auer, 
T. Campbell, D. De Witt, M. Figa, M. Figueiredo, A. Horhota, S. Low, 
K. McDonnell, E. Peeke, B. Retnarajan, A. Sabnis, E. Schnipper, 
J. J. Song, Y. H. Song, J. Summa, D. Tompsett, G. Troiano, 
T. Van Geen Hoven, J. Wright, P. LoRusso, P. W. Kantoff, 
N. H. Bander, C. Sweeney, O. C. Farokhzad, R. Langer, S. Zale, Sci. 
Transl. Med. 2012, 4, 128ra39.
[32] R. R. Castillo, M. Colilla, M. Vallet-Regí, Expert Opin. Drug Delivery 
2017, 14, 229.
[33] X. Lu, Y. Tian, Q. Zhao, T. Jin, S. Xiao, X. Fan, Nanotechnology 2011, 
22, 055101.
[34] A. Parveen, S. H. Rizvi, A. Gupta, R. Singh, I. Ahmad, F. Mahdi, 
A. A. Mahdi, Cell Mol. Biol. 2012, 58, 196.
[35] S.-M. Huang, X. Zuo, J. J. Li, S. F. Y. Li, B. H. Bay, C. N. Ong, Adv. 
Healthcare Mater. 2012, 1, 779.
[36] X. Lu, C. Ji, T. Jin, X. Fan, Nanotechnology 2015, 26, 175101.
[37] F. G. Omenetto, D. L. Kaplan, Science 2010, 329, 528.
[38] F. P. Seib, D. L. Kaplan, Isr. J. Chem. 2013, 53, 756.
[39] T. Yucel, M. L. Lovett, D. L. Kaplan, J. Controlled Release 2014, 190, 
381.
[40] G. H. Altman, F. Diaz, C. Jakuba, T. Calabro, R. L. Horan, J. Chen, 
H. Lu, J. Richmond, D. L. Kaplan, Biomaterials 2003, 24, 401.
[41] F. P. Seib, G. T. Jones, J. Rnjak-Kovacina, Y. Lin, D. L. Kaplan, Adv. 
Healthcare Mater. 2013, 2, 1606.
[42] F. P. Seib, D. L. Kaplan, Biomaterials 2012, 33, 8442.
[43] E. M. Pritchard, P. B. Dennis, F. Omenetto, R. R. Naik, D. L. Kaplan, 
Biopolymers 2012, 97, 479.
[44] M. T. Santini, G. Rainaldi, A. Ferrante, R. Romano, S. Clemente, 
A. Motta, B. De Berardis, M. Balduzzi, L. Paoletti, P. L. Indovina, 
Chem. Res. Toxicol. 2004, 17, 63.
[45] L. Liu, Y. Lu, J. Martinez, Y. Bi, G. Lian, T. Wang, S. Milasta, J. Wang, 
M. Yang, G. Liu, D. R. Green, R. Wang, Proc. Natl. Acad. Sci. USA 
2016, 113, 1564.
[46] A. Michelucci, T. Cordes, J. Ghelfi, A. Pailot, N. Reiling, 
O. Goldmann, T. Binz, A. Wegner, A. Tallam, A. Rausell, M. Buttini, 
C. L. Linster, E. Medina, R. Balling, K. Hiller, Proc. Natl. Acad. Sci. 
USA 2013, 110, 7820.
[47] A. K. Jha, S. C. Huang, A. Sergushichev, V. Lampropoulou, 
Y. Ivanova, E. Loginicheva, K. Chmielewski, K. M. Stewart, J. Ashall, 
B. Everts, E. J. Pearce, E. M. Driggers, M. N. Artyomov, Immunity 
2015, 42, 419.
[48] B. Németh, J. Doczi, D. Csete, G. Kacso, D. Ravasz, D. Adams, 
G. Kiss, A. M. Nagy, G. Horvath, L. Tretter, A. Mócsai, 
R. Csépányi-Kömi, I. Iordanov, V. Adam-Vizi, C. Chinopoulos, 
FASEB J. 2016, 20, 286.
[49] G. M. Tannahill, A. M. Curtis, J. Adamik, E. M. Palsson-McDermott, 
A. F. McGettrick, G. Goel, C. Frezza, N. J. Bernard, B. Kelly, 
N. H. Foley, L. Zheng, A. Gardet, Z. Tong, S. S. Jany, S. C. Corr, 
M. Haneklaus, B. E. Caffrey, K. Pierce, S. Walmsley, F. C. Beasley, 
E. Cummins, V. Nizet, M. Whyte, C. T. Taylor, H. Lin, S. L. Masters, 
E. Gottlieb, V. P. Kelly, C. Clish, P. E. Auron, R. J. Xavier, 
L. A. O’Neill, Nature 2013, 496, 238.
[50] T. Ravasi, C. Wells, A. Forrest, D. M. Underhill, B. J. Wainwright, 
A. Aderem, S. Grimmond, D. A. Hume, J. Immunol. 2002, 168, 44.
[51] A. R. Murphy, D. L. Kaplan, J. Mater. Chem. 2009, 19, 6443.
[52] O. Zabirnyk, M. Yezhelyev, O. Seleverstov, Autophagy 2007, 3, 278.
[53] S. D. Lamour, B. S. Choi, H. C. Keun, I. Müller, J. Saric, J. Proteome 
Res. 2012, 11, 4211.
[54] T. Wallimann, M. Wyss, D. Brdiczka, K. Nicolay, H. M. Eppenberger, 
Biochem. J. 1992, 281, 21.
[55] J. D. Loike, V. F. Kozler, S. C. Silverstein, J. Exp. Med. 1984, 159, 746.
[56] J. D. Loike, V. F. Kozler, S. C. Silverstein, J. Biol. Chem. 1979, 254, 
9558.
[57] J. Marcinkiewicz, A. Grabowska, J. Bereta, T. Stelmaszynska, J. Leu-
kocyte Biol. 1995, 58, 667.
[58] Y. Song, R. Zhao, Y. Hu, F. Hao, N. Li, G. Nie, H. Tang, Y. Wang, 
J. Proteome Res. 2015, 14, 5193.
[59] T. Wongpinyochit, P. Uhlmann, A. J. Urquhart, F. P. Seib, Biomacro-
molecules 2015, 16, 3712.
[60] T. Wongpinyochit, B. F. Johnston, F. P. Seib, J. Vis. Exp.,  2016, 116, 
e54669.
[61] F. P. Seib, K. Muller, M. Franke, M. Grimmer, M. Bornhauser, 
C. Werner, Tissue Eng., Part A 2009, 15, 3161.
[62] M. Yu, S. K. Selvaraj, M. M. Liang-Chu, S. Aghajani, M. Busse, 
J. Yuan, Nature 2015, 520, 307.
[63] J. Carrola, V. Bastos, J. M. Ferreira de Oliveira, H. Oliveira, 
C. Santos, A. M. Gil AM, I. F. Duarte, Arch. Biochem. Biophys. 2016, 
589, 53.
[64] D. S. Wishart, T. Jewison, A. C. Guo, M. Wilson, C. Knox, Y. Liu, 
Y. Djoumbou, R. Mandal, F. Aziat, E. Dong, S. Bouatra, I. Sinelnikov, 
D. Arndt, J. Xia, P. Liu, F. Yallou, T. Bjorndahl, R. Perez-Pineiro, 
R. Eisner, F. Allen, V. Neveu, R. Greiner, A. Scalbert, Nucleic Acids 
Res. 2013, 41, D801.
